BioMS brings New hope for Multiple Sclerosis Patients with a progressive form this disease

The potential to capture the Progressive Multiple Sclerosis Market.
• Up to 75% of MS patients carry either HLA-DR2 or HLA-DR4 immune response genes.
• MBP8298 demonstrated statistically significant clinical results in patients with these genes.

Statistically Significant Results in Patients with HLA-DR2 or HLA-DR4 Genes
MBP8298 is entering late-stage trials in secondary progressive MS
BioMS Medical Corp. is a development stage company, with its primary focus being the development
and commercialization of a medical treatment for multiple sclerosis.


Click this link: http://www.biomsmedical.com/userfiles/file/bioms-annual-report-2003.pdf
for further information


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================